Compare Anheuser-Busch Inbev SA (BUD) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs Medtronic PLC — how do they compare? Anheuser-Busch Inbev SA trades at $79.54 (market cap $159.01B), while Medtronic PLC trades at $88.99 (market cap $116.07B). The key difference: Anheuser-Busch Inbev SA is the larger of the two by market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| BUD | MDT | |
|---|---|---|
Market Cap | $159.01B | $116.07B |
Sector | Consumer Staples | Health |
52-Week High | $86.48 | $105.35 |
52-Week Low | $57.93 | $73.75 |
Enterprise Value | $223.42B | $134.82B |
Dividend Yield | 1.67% | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $83.09, down 0.8% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating in Q1 and Q2 2026 but missing in Q4 2025. The company maintains solid profitability with a 14.9% net income margin and positive cash flow trends. News highlights institutional activity and earnings discussions, with a consensus price target of $90.17 suggesting upside potential.
The outlook for BUD is positive, driven by earnings growth projections and a favorable valuation with a P/E of 17.37. Risks include competitive pressures and macroeconomic volatility, but institutional support and bullish analyst ratings indicate confidence in continued performance. The stock presents a growth opportunity with manageable risks for investors seeking exposure to the consumer staples sector.
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
